Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Cardiff Oncology Inc. maintains 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners and 4 distinct art units, showing a distribution of the portfolio across the patent office. This spread suggests that the company is pursuing multiple distinct innovations simultaneously, each requiring a different examiner's review.
BRAUN, MADELINE E is the busiest examiner for the company, holding 1 pending office action. Because each of the 5 examiners handles only 1 action, the prosecution workload is evenly dispersed across the individuals involved. However, the use of 4 distinct art units for 5 actions indicates that at least some actions are being processed within the same art unit, even if the examiners themselves are different individuals. This administrative arrangement requires the company to track separate prosecution timelines for the 5 pending office actions across these 4 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
| MCKOY, QUINCY ANDRE | 1 | 68.8% | +39.4% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 46.9% | +81.0% |
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710027 | CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS | BRAUN, MADELINE E | — |
| 18554158 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | MCKOY, QUINCY ANDRE | — |
| 17598665 | PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER | BELL, SARA ELIZABETH | — |
| 17433440 | ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION | MOU, LIYUAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923803 | METHODS OF MONITORING KRAS MUTATIONS | JOHNSON, CHRISTOPHER LINDSAY | 13d |
| 18710027 | CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS | BRAUN, MADELINE E | — |
| 18554158 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | MCKOY, QUINCY ANDRE | — |
| 17598665 | PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER | BELL, SARA ELIZABETH | — |
| 17433440 | ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1691 | 1 |
| 1625 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18710027 | CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS | BRAUN, MADELINE E | — | §103§112 | Non-Final OA | — | Pending | May 14, 2024 |
| 18554158 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | MCKOY, QUINCY ANDRE | 1626 | §103§112 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 17923803 | METHODS OF MONITORING KRAS MUTATIONS | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §112 | Non-Final OA | 13d | Pending | Apr 28, 2023 |
| 17598665 | PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER | BELL, SARA ELIZABETH | 1625 | §103§112 | Final Rejection | — | Pending | Sep 27, 2021 |
| 17433440 | ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION | MOU, LIYUAN | 1628 | §103§112 | Final Rejection | — | Pending | Aug 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial